Novartis India shares hit record after ₹1,250 crore Minipress deal with Pfizer

Novartis India pays ₹1,250 crore for Pfizer's Minipress brands

Novartis India agreed to acquire the "Minipress" and "Minipres" trademarks and related intellectual property in India from Pfizer Inc. and Pfizer Products Inc. for ₹1,250 crore. The boards of both companies cleared the asset purchase agreement and trademark assignment deed on September 7, 2026, completing a full transition of the franchise. Pfizer officially discontinued marketing and distribution of the products in India as of the same date.

Stock hits 52-week high on three-day rally

Novartis India's share price climbed as much as 13% intraday on Thursday to a record ₹2,474.90, after gaining roughly 51% across the previous three trading sessions. The rally pushed the stock to a fresh 52-week high, while broader Indian equity benchmarks moved little. A separate report on the deal's first trading session recorded Novartis India up about 20% and Pfizer down about 3%, reflecting the opposite market reaction to the transaction.

Minipress XL sales and growth profile

The acquired brand is centered on Minipress XL, a prazosin-based therapy used in India for hypertension and the symptoms of benign prostatic hyperplasia. According to IQVIA MAT data for July 2026 cited in the coverage, Minipress XL generated about ₹228.6 crore in Indian sales. The brand grew at a roughly 6.3% compound annual rate over the past four years, compared with about 9% for the broader cardiovascular and urology therapy category, indicating a more mature growth profile.

Deal follows ChrysCapital takeover at Novartis India

The transaction follows the July 2026 completion of private equity firm ChrysCapital's 70.68% majority stake takeover of Novartis India. Coverage described the Minipress acquisition as part of the new management's effort to strengthen the company's footprint in cardiovascular and urology therapeutics. The combined handover from Pfizer and the ownership change at Novartis India form the backdrop for the deal.

What to watch next

Investors and analysts are expected to track how the Minipress portfolio contributes to Novartis India's revenue and whether the new owners can lift growth above the wider therapy category's pace. Subsequent earnings disclosures from Novartis India and any integration updates under ChrysCapital's majority ownership are likely to serve as the next verification points for the deal's impact.

Research Summary (citation source reference)

Primary topic: Novartis India's ₹1,250 crore acquisition of Pfizer's Minipress and Minipres trademarks and intellectual property in India, announced on September 7, 2026. The deal triggered a 51% three-day share price rally to a ₹2,474.90 record, against the backdrop of ChrysCapital's July 2026 70.68% takeover of Novartis India and Minipress XL's ₹228.6 crore Indian sales growing at 6.3% CAGR versus 9% for the broader category.